Can adrenocortical cancer be controlled by taking Mitotane?

Adrenocortical carcinoma (Adrenocortical Carcinoma, ACC) is a rare but aggressive cancer that originates in the adrenal cortex tissue. Mitotane (Mitotane) is often one of the first-line treatment options for ACC. Its main function is to inhibit the function of adrenocortical cells, reduce the secretion of adrenocortical hormones, and inhibit the growth of tumor cells.

For many patients with ACC, the use of mitotane can help control tumor growth and reduce tumor-related symptoms, such as high blood pressure and metabolic disorders. It can prolong the patient's survival to a certain extent. However, ACC is often an aggressive cancer, its treatment course is often complex, and complete cure is often difficult.

The effectiveness of mitotane will vary on an individual basis, and not all patients will respond to it in the same way. Some patients respond well to mitotane treatment, with tumors under control and survival prolonged. However, some patients may respond poorly to mitotane treatment or develop drug resistance.

When treatingACC, multi-level and comprehensive treatment strategies are usually used, including surgical removal of tumors, radiation therapy, chemotherapy and other treatments. Mitotane is often used as part of this treatment to control tumor growth and reduce symptoms.

Mitotane has not yet been launched in China, so patients cannot purchase it domestically and need to purchase it through overseas channels. There are original drugs and generic drugs abroad. The Turkish version of the original drug is about more than 7,000 yuan, followed by the European version of the original drug, which is about 9,000 yuan. There are also cost-effective generic drugs, mainly Laos and ASEAN generic drugs. The price is about more than 3,000 yuan. The ingredients of the original drugs and generic drugs are the same.